Q&A

Highly Potent APIs Are Becoming More Potent And Complex

Evonik

Dr. Andreas Meudt is the global head of Exclusive Synthesis for Evonik, one of the world’s top three CMOs for APIs and the largest for highly potent APIs (HPAPIs). In this interview, Dr. Meudt shares his thoughts on key growth trends for HPAPIs, and why more pharma companies are outsourcing their production to contract specialists.

VIEW THE Q&A!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Pharmaceutical Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: